Alterity Therapeutics Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

376.22

EPS

—

Div Yield, %

—

Shrs. gr., 5y

413.07%

Rev. gr., 5y

105.93%

Revenues

+2.63%

Net income

-19m

L+38.51%

CFO

-13m

L-37.08%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Alterity Therapeutics Limited, an Australian-based company, is dedicated to the discovery and development of pharmaceutical treatments for a range of neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases. The firm's leading experimental medication, ATH434, has successfully concluded its Phase I clinical trials for Parkinson's disease. Furthermore, Alterity is advancing PBT2, a compound that has already completed Phase IIa clinical trials targeting Alzheimer's disease. Formed in 1997 and headquartered in Melbourne, Australia, the company rebranded from Prana Biotechnology Limited to Alterity Therapeutics Limited in April 2019.

URL

https://alteritytherapeutics.com/

IPO date

Mar 28, 2000

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title AUD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title AUD in thousands, except ratios and share amounts	2025‑06	2024‑06	2023‑06	2022‑06	2021‑06	2020‑06	2019‑06	2018‑06	2017‑06	2016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT